Coronary Heart Disease—ACE Inhibitors for all Patients? Kalman TothIstvan CzurigaIstvan Edes Editorial Introduction Pages: 391 - 393
The Almost Forgotten Biological Potentials of Cholesterol and its Intermediates: Cholesterol Reduction and Myositis Marcel TwicklerJan Dirk BangaMaarten-Jan Cramer Editorial Introduction Pages: 395 - 396
Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2A Receptor Agonist: Role of A2A Receptor and Erk1/2 Adrienn KisGary F. BaxterDerek M. Yellon OriginalPaper Pages: 415 - 425
Effects of EGIS-7625, a Selective and Competitive 5-HT2B Receptor Antagonist Anikó KovácsIstvan GacsályiGábor Szénási OriginalPaper Pages: 427 - 434
Selective Block of Sarcolemmal IKATP in Human Cardiomyocytes Using HMR 1098 Stefan KääbLudwig ZwermannMichael Näbauer OriginalPaper Pages: 435 - 441
Comparison of Cholesterol-Lowering Efficacy and Anti-Atherogenic Properties of Hydrogenated versus Non-Hydrogenated (Phytrol™) Tall Oil-Derived Phytosterols in Apo E-Deficient Mice P. Haydn PritchardMin LiMohammed H. Moghadasian OriginalPaper Pages: 443 - 449
Pharmacodynamic Interactions of Levosimendan and Felodipine in Patients with Coronary Heart Disease Pentti PõderJaan EhaLasse Lehtonen OriginalPaper Pages: 451 - 458
A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs Sylvia FrancSylvie DejagerGérard Turpin OriginalPaper Pages: 459 - 465
The Role of Clopidogrel in the Management of Patients with Ischemic Heart Disease V. ChopraJ.D. MarmurE. Cavusoglu ReviewPaper Pages: 467 - 477